60 DEGREES PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $46.98 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- 60 DEGREES PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $46.98K, a 36.16% increase year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $79.52K, a 44.25% decline year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $67.84K, a 287.21% increase year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $34.88K, a 128.79% increase year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $279.87K, a 754.13% increase from fiscal 2024.
- 60 DEGREES PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $32.77K, a 72.52% decline from fiscal 2023.
- 60 DEGREES PHARMACEUTICALS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $119.25K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.98K 10-Q · filed 2026-08-14 | $126.50K 10-Q · filed 2026-08-14 | $194.34K derived: sum of 3 quarters · filed 2026-08-14 | $229.23K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $79.52K 10-Q · filed 2026-08-14 | $147.37K derived: sum of 2 quarters · filed 2026-08-14 | $182.25K derived: sum of 3 quarters · filed 2026-08-14 | $216.75K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $67.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $102.72K derived: sum of 2 quarters · filed 2026-03-30 | $137.23K derived: sum of 3 quarters · filed 2026-08-14 | $279.87K 10-K · filed 2026-03-30 |
| 2025-09-30 | $34.88K 10-Q · filed 2025-11-13 | $69.39K derived: sum of 2 quarters · filed 2026-08-14 | $212.03K 10-Q · filed 2025-11-13 | $229.55K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $34.50K 10-Q · filed 2026-08-14 | $177.15K 10-Q · filed 2026-08-14 | $194.67K derived: sum of 3 quarters · filed 2026-08-14 | $209.91K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $142.65K 10-Q · filed 2026-08-14 | $160.17K derived: sum of 2 quarters · filed 2026-08-14 | $175.41K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2024-12-31 | $17.52K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $32.77K derived: sum of 2 quarters · filed 2026-03-30 | $32.77K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $15.25K 10-Q · filed 2025-11-13 | $15.25K 10-Q · filed 2025-11-13 | ||
| 2023-12-31 | $119.25K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $271.07K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 |